This video analyzes United Health (UNH) stock following a significant price decline. The company, the largest US health insurer with substantial revenue and diversified segments including the growing Optum health services division (pharmacy benefits, care delivery, data analytics), recently saw its stock price drop over 50% from highs, trading at a low price-to-earnings ratio of around 11.
The primary reasons for the downturn are explored, including a downward revision and subsequent withdrawal of 2025 earnings guidance due to higher-than-expected care utilization costs in Medicare Advantage plans. Compounding the uncertainty were the unexpected resignation of the CEO and increasing legal scrutiny, including a class-action lawsuit alleging securities fraud through improper claim denials. Furthermore, potential regulatory changes under a possible future Trump administration aiming to lower healthcare costs add another layer of risk.
Despite some business segments showing continued revenue growth and previous CEO statements expressing confidence in a return to historical growth rates by 2026, the speaker concludes that the level of uncertainty surrounding the business's future profitability and regulatory environment is too high for him to consider it an attractive investment currently, placing it outside his circle of competence despite the seemingly low valuation.
Analysis of United Health Stock After Recent Decline
0:00 - 0:30 The video focuses on United Health (UNH) stock, noting its high visibility and discussion on social media following a significant price drop.
0:30 - 1:08 United Health is described as the largest health insurer in the US with over $400 billion in annual revenue. The stock recently dropped 54% from its highs and is trading at a historically low price-to-earnings ratio of about 11, despite a track record of growth.
1:10 - 2:27 The company has two main segments: United Healthcare (insurance) and Optum (health services). Optum includes Optum Health (care delivery), Optum RX (pharmacy benefits), and Optum Insight (data analytics/technology), which processes 2.4 trillion healthcare transactions annually, providing a competitive data advantage. Optum has been the primary growth engine.
2:27 - 2:46 United Health dominates employer-sponsored insurance, serving 80% of Fortune 100 companies and covering 180 million Americans, presenting a significant moat.
2:47 - 3:34 The company's Q1 2025 report showed revenue growth of 8-9% year-over-year to $109.6 billion (an all-time high), with consolidated operating earnings increasing and operating margin expanding. Certain segments like Medical and Retirement, Community and State, and Optum RX showed strong 15% growth.
4:00 - 4:51 The primary reason for the stock decline was a revised, lower 2025 guidance (from ~$30 to ~$26 EPS) due to an unexpected spike in care utilization within Medicare Advantage plans, especially among new, previously low-cost patients. This put pressure on profit margins.
4:53 - 6:23 In the Q1 transcript, the CEO expressed confidence that these margin pressures were addressable and expected to dissipate by 2026 through various initiatives, including engaging complex patients, home/post-discharge member engagement, updating patient health status, improving physician workflow, and informing 2026 plan designs/pricing.
6:26 - 7:13 The CEO also stated dissatisfaction with results but affirmed a solid growth foundation, expecting to serve an additional 800,000 Medicare Advantage people in 2025.
7:13 - 7:29 He committed to improving performance and returning to the long-term earnings per share growth target of 13-16% annually in 2026, which was the historical average.
8:08 - 9:07 On May 14th, the CEO unexpectedly stepped down for personal reasons. Simultaneously, United Health suspended its financial outlook for 2025 entirely, citing Medicare Advantage costs remaining higher than expected. This withdrawal of guidance indicates significant uncertainty about current year earnings.
10:09 - 11:37 Further concerns include increased scrutiny and lawsuits following the former CEO's public incident in 2024. A judge ruled a lawsuit over AI care denials could proceed, and a class-action lawsuit for securities fraud was filed alleging the company improperly denied claims to boost profits, a claim the speaker finds serious and ethically concerning.
11:39 - 12:43 Potential regulatory risk from a possible future Trump administration aims to reform healthcare, target pharmacy benefit managers (like Optum RX), lower drug prices (using international price comparisons), and increase pricing transparency, creating uncertainty about future profitability.
12:44 - 13:27 Summarizing the negative factors: controversies over denying healthcare, investigations, lowered/withdrawn 2025 guidance, CEO departure, multiple lawsuits (AI denial, securities fraud), and regulatory risk. This accumulation of issues explains the stock's significant drop and surrounding uncertainty.
13:27 - 14:18 Financial data shows revenue is at an all-time high (trailing 12 months), but net income is slightly down compared to the end of 2023, indicating declining profit margins. The current P/E is 11.4, with analysts forecasting a forward P/E of 9.84.
14:18 - 15:07 The low P/E ratio appears attractive if the company can resolve issues and return to 13-16% growth in 2026. However, the speaker notes that if earnings decline, the P/E ratio would rise from its current level.
15:07 - 17:10 The speaker emphasizes that he has no certainty about the future profit potential due to the unresolved issues, lawsuits, and political factors. While stock drops of 50% can be opportunities in uncertain times (like his investment in Amazon in 2022), he needs high conviction in future profits.
17:10 - 17:18 With United Health, he lacks this certainty regarding the impact of the new administration and lawsuits on future outcomes.
17:18 - 17:52 He concludes that UNH is outside his circle of competence; he won't buy it simply because it's down, stating he prefers more certain opportunities.
17:52 - 19:20 The perceived bullish thesis ("too big to fail") seems like hoping the company figures it out, which isn't enough conviction for him. He emphasizes sticking to one's strategy and competence, even if others outperform.
19:50 - 20:04 He reiterates that not every investor needs to jump on opportunities just because a stock is down and other people are buying it.
20:04 - 20:17 He places UNH in his "too hard" pile and will not touch it, wishing well to those who choose to buy it.